Table 1 Base-case results over lifetime horizon

From: Cost-effectiveness analysis of screening for congenital Chagas disease in a non-endemic area

Strategy

Costs (€) (95% CI)

Δ costs (€)

QALYs (95% CI)

Δ QALYs

ICER

NMB (€)

Screening

4,189,067 (4,119,027–4,542,211)

–

31,608 (30,122– 32,467)

–

Ref.

–

No screening

57,414 (57,402 –58,256)

4,131,653

31,336 (31,134– 31,578)

272

15,192

9,465,847

  1. CI confidence intervals, ICER incremental cost-effectiveness ratio, NMB net monetary benefit.
Back to article page